Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies
European Urology Focus · 2025-03 · 11 (2) · 374-385
DOI: 10.1016/j.euf.2024.11.003 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Urology Focus, 2025-03. Verfasst von Akihiro Matsukawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). It is highly invasive and associated with perioperative risks, while bladder-preserving trimodality therapy (TMT) offers a less invasive alternative with preferable quality of life for selected patients. We aimed to compare oncological outcomes of TMT and RC in MIBC patients, and evaluate TMT-specific outcomes. METHODS: In December 2023, PubMed, Scopus, and Web of Science were searched for studies on MIBC patients treated with TMT. Pairwise meta-analyses were conducted to compare overall survival (OS) and cancer-specific survival (CSS) between MIBC patients treated with TMT and RC, utilizing hazard ratios (HRs). We included only matched cohort studies to minimize selection bias. TMT-specific outcomes, such as response, recurrence, and toxicity rates, were pooled separately. KEY FINDINGS AND LIMITATIONS: Eighty-seven studies (n = 28 218) were identified. No significant differences in OS (HR: 1.05; 95% confidence interval [CI]: 0.78-1.40) and CSS (HR: 1.05; 95% CI: 0.69-1.58) were found for TMT compared with RC. In patients treated with TMT, the complete response was achieved in 74.4% (95% CI: 69.1-79.1), the estimated rate of intravesical recurrence was 23.1% (95% CI: 19.0-27.7), and the rate of grade ≥3 acute toxicity was 11.4% (95% CI: 4.0-28.4). CONCLUSIONS AND CLINICAL IMPLICATIONS: The oncological outcomes of TMT were comparable with those of RC, with an acceptable toxicity profile. TMT appears as a safe and effective treatment for appropriately selected MIBC patients who want to preserve their bladder. However, evidence from high-volume controlled trials is needed. PATIENT SUMMARY: Well-selected patients with nonmetastatic muscle-invasive bladder cancer can be treated with "trimodality therapy" to preserve the bladder. So far, the reported outcomes are comparable with those of radical surgery, and we found no signs of excess toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Department of Urology, IRCCS Humanitas R…
Zitieren
APA
Matsukawa, A., Yanagisawa, T., Miszczyk, M., Kardoust Parizi, M., Fazekas, T., Tsuboi, I., Mancon, S., Klemm, J., Schulz, R., Cadenar, A., Laukhtina, E., Rajwa, P., Mori, K., Miki, J., Kimura, T., & Shariat, S. F. (2025). Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies. European Urology Focus, 11(2), 374-385. https://doi.org/10.1016/j.euf.2024.11.003
Vancouver
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al. Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies. European Urology Focus. 2025;11(2):374-385. doi:10.1016/j.euf.2024.11.003
BibTeX
@article{Matsukawa2025,
author = {Matsukawa, Akihiro and Yanagisawa, Takafumi and Miszczyk, Marcin and Kardoust Parizi, Mehdi and Fazekas, Tamás and Tsuboi, Ichiro and Mancon, Stefano and Klemm, Jakob and Schulz, Robert and Cadenar, Anna and Laukhtina, Ekaterina and Rajwa, Paweł and Mori, Keiichiro and Miki, Jun and Kimura, Takahiro and Shariat, Shahrokh F},
title = {Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies},
journal = {European Urology Focus},
year = {2025},
volume = {11},
number = {2},
pages = {374--385},
doi = {10.1016/j.euf.2024.11.003}
}
EUVIMED